Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
TACE-Len-T treatment significantly improved OS, PFS, ORR, and DCR over TACE-Len treatment, with a manageable safety profile in uHCC.
Authors
- Jiayun Jiang (ORCID: https://orcid.org/0000-0002-0802-5750)
- Leida Zhang (ORCID: https://orcid.org/0000-0002-3870-7410)
- Yanjiao Ou
- Yu Fu (ORCID: https://orcid.org/0000-0002-8960-5000)
- Hui Zhang (ORCID: https://orcid.org/0000-0001-6825-5649)
- Shiyu Zhang (ORCID: https://orcid.org/0000-0002-3645-3891)
- Jiejuan Lai
Institutions
- Southwest University (CN)
- Army Medical University (CN)
- Southwest Hospital (CN)
- Chongqing Medical and Pharmaceutical College (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/jhc.s472286
- Citations
- 5
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.85
Funders
- Centre Scientifique et Technique du Bâtiment